By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Athera Biotechnologies 

Delaware Technology Park
5 Innovation Way, Suite 100
Newark  Delaware  19711  U.S.A.
Phone: 302-224-3450 Fax: 302-224-3457



Company News
Athera Biotechnologies Receives FDA Orphan Drug Designation For PC-mAB In Prevention Of Vascular Access Failure In Kidney Disease Patients 6/21/2017 9:13:45 AM
Athera Biotechnologies Release: Proteomics Used To Investigate Effects On Inflammation Response Following Vascular Surgery And Treatment With The Immunovascular Antibody PC-mAb 5/15/2017 11:51:12 AM
Athera Biotechnologies Completes First-In-Patient Study With New Antibody Against Immunovascular Disease 8/11/2016 8:30:03 AM
Athera Biotechnologies Completes 24 Million SEK financing 12/3/2015 11:24:53 AM
Karolinska Development AB Divests Its Holding In Athera Biotechnologies 12/3/2015 10:31:18 AM
Athera Biotechnologies Initiates Phase I Trial With Its Fully Human Antibody PC-mAb 10/21/2014 10:54:58 AM
Athera Biotechnologies and Boehringer Ingelheim Corporation Enter Into an Option Agreement on a Novel Therapy for Atherosclerosis 6/19/2013 9:38:50 AM
Karolinska Development AB: EU Grants EUR 6 Million to the Clinical Development of Athera Biotechnologies' Cardiovascular Disease Antibody Therapy 6/17/2013 9:28:38 AM
EU Grants EUR 6M to the Clinical Development of Athera Biotechnologies's Cardiovascular Disease Antibody Therapy 6/17/2013 9:04:51 AM
Lonza Inc. Signs Development and Manufacturing Agreement with Emerging Biotech Company Athera Biotechnologies 3/17/2011 9:43:21 AM